Document is current
Any future updates will be listed below
-
Authors
Feng, Bing-Jian https://orcid.org/0000-0002-6669-6640
Kohlmann, Wendy
Nix, David A
Atkinson, Aaron
Boucher, Kenneth M
Carroll, Courtney https://orcid.org/0000-0003-4906-549X
Stubben, Chris J
Kolesar, Jill
Singer, Eric A
Riedlinger, Gregory
Edge, Stephen
Sahu, Kamal Kant
Churchman, Michelle
Graham, Laura
Salhia, Bodour
Sanchez, Alejandro
Zakharia, Yousef https://orcid.org/0000-0001-9480-2626
Schneider, Bryan P
Jain, Rohit
Byrne, Lindsey https://orcid.org/0000-0001-7131-5331
Moskaluk, Christopher A
Nepple, Kenneth
Shabsigh, Ahmad
Chahoud, Jad
Cairns, Bradley R
Gupta, Sumati https://orcid.org/0000-0001-6271-0831
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02108652 at ClinicalTrials.govDocuments that mention this clinical trial
Single-cell analysis reveals clonally expanded tumor-associated CD57 <sup>+</sup> CD8 T cells are enriched in the periphery of patients with metastatic urothelial cancer responding to PD-L1 blockade
https://doi.org/10.1136/jitc-2022-004759
Treatment-emergent antidrug antibodies related to PD-1, PD-L1, or CTLA-4 inhibitors across tumor types: a systematic review
https://doi.org/10.1136/jitc-2023-008266
NKG2A and PD-L1 expression panel predicts clinical benefits from adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer
https://doi.org/10.1136/jitc-2022-004569
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
https://doi.org/10.1016/s0140-6736(16)00561-4
1197 Harnessing the cancer immunity cycle via machine learning models to generate novel strategies for personalized cancer therapy
https://doi.org/10.1136/jitc-2024-sitc2024.1197
Fibroblast growth factor receptor 3 mutation attenuates response to immune checkpoint blockade in metastatic urothelial carcinoma by driving immunosuppressive microenvironment
https://doi.org/10.1136/jitc-2022-006643
Primary and secondary pseudo-stability and progression after atezolizumab with and without bevacizumab
https://doi.org/10.1136/jitc-2025-013727
Tumor-agnostic transcriptome-based classifier identifies spatial infiltration patterns of CD8+T cells in the tumor microenvironment and predicts clinical outcome in early-phase and late-phase clinical trials
https://doi.org/10.1136/jitc-2023-008185
Identification of a conserved subset of cold tumors responsive to immune checkpoint blockade
https://doi.org/10.1136/jitc-2024-010528
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer
https://doi.org/10.1136/jitc-2021-002552
Germline whole-exome sequencing reveals <i>FOXP3</i>-related gene variants conferring urinary cancer susceptibility and associated with immune escape
https://doi.org/10.1136/jitc-2024-010417
Intratumoral CD103+ CD8+ T cells predict response to PD-L1 blockade
https://doi.org/10.1136/jitc-2020-002231
-
Funding
Funding for this research was provided by:
Chan Soon-Shiong Family Foundation
Huntsman Cancer Foundation
National Cancer Institute (P30CA042014)
National Institutes of Health (1S10OD021644-01A1)
U.S. Department of Veterans Affairs (1T01 BX005765)
- License Information
